Hier sehen Sie einige ausgewählte Beispielbeiträge aus unserer Datenbank.
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer
Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients
Bisphosphonate Use After Estrogen Receptor-Positive Breast Cancer and Risk of Contralateral Breast Cancer
Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
A Prospective, Controlled Study of the Botanical Compound Mixture LCS101 for Chemotherapy-Induced Hematological Complications in Breast Cancer
Breast cancer after hormone replacement therapy – does prognosis differ in perimenopausal and postmenopausal women?
Phase III Study of Doxorubicin / Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial
